Under 10% of people eligible to benefit from GLP-1 drugs like Wegovy are able to get them, states the WHO as it releases its first recommendations on the therapies.
With in excess of 1,000,000,000 people worldwide now obese, it is urging increased and just availability to these injectable treatments.
According to forecasts, more than two billion will be obese by 2030 unless action is taken.
"The latest guidance acknowledges that excess weight is a lifelong illness that can be treated with thorough and continuous care," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are significant barriers to universal availability to the jabs that can help people shift significant weight, says the agency.
Skinny Jab Shortage
Despite the current most optimistic case, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – less than 10% of those who need them, as stated by the WHO.
The advice urges governments and firms to increase availability, via strategies including voluntary licensing.
The intellectual property rights on the active ingredient – the primary component of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Drugs Work
These medications imitate a natural hormone to reduce digestion speed, curb appetite and boost satiety so people eat less.
Patients typically start to lose weight in the initial weeks of commencing the weekly injections.
Research points to people may put most of the weight back on within a year of stopping the drug, when their usual hunger return.
To be above a healthy weight raises your risk for experiencing medical conditions, including diabetes, cardiovascular issues, brain attack, and certain malignancies.
Excess weight affects people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
